1097920-54-1

Basic information

• Product Name: tert-butyl 4-(3-methoxy-4-nitrophenoxy)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(3-methoxy-4-nitrophenoxy)piperidine-1-carboxylate
• CAS NO: 1097920-54-1
• Molecular Weight: 352.387
• Mol File: 1097920-54-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(3-methoxy-4-nitrophenoxy)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(3-methoxy-4-nitrophenoxy)piperidine-1-carboxylate(1097920-54-1)
• EPA Substance Registry System: tert-butyl 4-(3-methoxy-4-nitrophenoxy)piperidine-1-carboxylate(1097920-54-1)

Safety Data

• Hazardous Substances Data: 1097920-54-1(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 16292-95-8 4-nitro-3-methoxyphenol 
• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 1097921-02-2 tert-butyl 4-(4-amino-3-methoxyphenoxy)piperidine-1-carboxylate 

Relevant articles and documents

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS

The present invention relates to compounds comprising an interleukin-1 receptor-associated kinase 1 (IRAK1) protein binding moiety and a Von Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety, and associated methods of use. The compounds are useful as modulators of targeted ubiquitination, especially with respect to IRAK1, which is degraded by the compounds according to the invention.

Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity

A series of chemical optimizations guided by in vitro affinity at a histamine H3 receptor (H3R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake-promoting effects with decreased rapid-eye-movement sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety studies in animals have been successfully completed without any concern for further development.

NOVEL COMPOUNDS 515

There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy